Detail akcie Oasmia Pharma online

Business Summary: Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Vivesto AB revenues was not reported. Net loss decreased 61% to SEK18.8M. Lower net loss reflects Sale of supplies segment loss decrease of 60% to SEK20.2M. Basic Earnings per Share excluding Extraordinary Items increased from -SEK0.09 to -SEK0.03.